Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Allogene Moves Forward With CAR-T Therapy Pipeline Summary Allogene Therapeutics established a partnership with Notch Therapeutics so that both companies can develop iPSC AlloCar therapy products. The pluripotent stem cells from Notch provide an inexhaustible source along with other advantages like developing T-cells and other immune cells from clonal stem cell lines. Allogene has already established its own AlloCAR T therapy for the treatment of hematological malignancies and solid tumors. Allogene Therapeutics has $601.9 million in cash as of September 30, 2019, which will be enough to fund operations 12 months from the November 5, 2019, 10-Q SEC Filing. Allogene Therapeutics ( ALLO latest partnership involves Notch Therapeutics Partnership Advances Deep Dive Into New Type Of nology Allogene Therapeutics has formed a worldwide collaboration and license agreement with Notch Therapeutics. This agreement was made so that both companies could research and develop iPSC AlloCAR therapy pr
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Q2 Investor Conference ParticipationGlobeNewswire
- We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside [Seeking Alpha]Seeking Alpha
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
ALLO
Earnings
- 3/14/24 - Miss
ALLO
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- ALLO's page on the SEC website